

James Shorter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/129152/publications.pdf>

Version: 2024-02-01

175
papers

20,667
citations

13827

67
h-index

11899

134
g-index

190
all docs

190
docs citations

190
times ranked

16831
citing authors

#	ARTICLE	IF	CITATIONS
1	Protein Phase Separation: A New Phase in Cell Biology. <i>Trends in Cell Biology</i> , 2018, 28, 420-435.	3.6	1,439
2	Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. <i>Nature</i> , 2013, 495, 467-473.	13.7	1,249
3	Stress granules as crucibles of ALS pathogenesis. <i>Journal of Cell Biology</i> , 2013, 201, 361-372.	2.3	756
4	TDP-43 Is Intrinsically Aggregation-prone, and Amyotrophic Lateral Sclerosis-linked Mutations Accelerate Aggregation and Increase Toxicity. <i>Journal of Biological Chemistry</i> , 2009, 284, 20329-20339.	1.6	651
5	The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. <i>Brain Research</i> , 2012, 1462, 61-80.	1.1	572
6	The molecular language of membraneless organelles. <i>Journal of Biological Chemistry</i> , 2019, 294, 7115-7127.	1.6	515
7	Neurodegenerative disease: models, mechanisms, and a new hope. <i>DMM Disease Models and Mechanisms</i> , 2017, 10, 499-502.	1.2	508
8	Prions as adaptive conduits of memory and inheritance. <i>Nature Reviews Genetics</i> , 2005, 6, 435-450.	7.7	500
9	The Parkinson's disease protein α -synuclein disrupts cellular Rab homeostasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 145-150.	3.3	479
10	Hsp104 Catalyzes Formation and Elimination of Self-Replicating Sup35 Prion Conformers. <i>Science</i> , 2004, 304, 1793-1797.	6.0	454
11	A complex of mammalian Ufd1 and Npl4 links the AAA-ATPase, p97, to ubiquitin and nuclear transport pathways. <i>EMBO Journal</i> , 2000, 19, 2181-2192.	3.5	404
12	Molecular Determinants and Genetic Modifiers of Aggregation and Toxicity for the ALS Disease Protein FUS/TLS. <i>PLoS Biology</i> , 2011, 9, e1000614.	2.6	396
13	Nuclear-Import Receptors Reverse Aberrant Phase Transitions of RNA-Binding Proteins with Prion-like Domains. <i>Cell</i> , 2018, 173, 677-692.e20.	13.5	376
14	A yeast functional screen predicts new candidate ALS disease genes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 20881-20890.	3.3	365
15	RNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43. <i>Neuron</i> , 2019, 102, 321-338.e8.	3.8	365
16	RNA-binding proteins with prion-like domains in health and disease. <i>Biochemical Journal</i> , 2017, 474, 1417-1438.	1.7	347
17	Golgi Architecture and Inheritance. <i>Annual Review of Cell and Developmental Biology</i> , 2002, 18, 379-420.	4.0	337
18	Cytoplasmic TDP-43 De-mixing Independent of Stress Granules Drives Inhibition of Nuclear Import, Loss of Nuclear TDP-43, and Cell Death. <i>Neuron</i> , 2019, 102, 339-357.e7.	3.8	331

#	ARTICLE	IF	CITATIONS
19	Poly(ADP-Ribose) Prevents Pathological Phase Separation of TDP-43 by Promoting Liquid Demixing and Stress Granule Localization. <i>Molecular Cell</i> , 2018, 71, 703-717.e9.	4.5	309
20	GRASP55, a second mammalian GRASP protein involved in the stacking of Golgi cisternae in a cell-free system. <i>EMBO Journal</i> , 1999, 18, 4949-4960.	3.5	287
21	The Mammalian Disaggregase Machinery: Hsp110 Synergizes with Hsp70 and Hsp40 to Catalyze Protein Disaggregation and Reactivation in a Cell-Free System. <i>PLoS ONE</i> , 2011, 6, e26319.	1.1	282
22	Prion-like disorders: blurring the divide between transmissibility and infectivity. <i>Journal of Cell Science</i> , 2010, 123, 1191-1201.	1.2	268
23	Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. <i>Human Molecular Genetics</i> , 2012, 21, 2899-2911.	1.4	246
24	Ratchet-like polypeptide translocation mechanism of the AAA+ disaggregase Hsp104. <i>Science</i> , 2017, 357, 273-279.	6.0	241
25	ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defects. <i>Journal of Clinical Investigation</i> , 2014, 124, 981-999.	3.9	225
26	Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models. <i>Nature Genetics</i> , 2012, 44, 1302-1309.	9.4	214
27	Potentiated Hsp104 Variants Antagonize Diverse Proteotoxic Misfolding Events. <i>Cell</i> , 2014, 156, 170-182.	13.5	205
28	Destruction or Potentiation of Different Prions Catalyzed by Similar Hsp104 Remodeling Activities. <i>Molecular Cell</i> , 2006, 23, 425-438.	4.5	197
29	Prion-like domains as epigenetic regulators, scaffolds for subcellular organization, and drivers of neurodegenerative disease. <i>Brain Research</i> , 2016, 1647, 9-18.	1.1	195
30	TDP-43 represses cryptic exon inclusion in the FTD/ALS gene UNC13A. <i>Nature</i> , 2022, 603, 124-130.	13.7	193
31	Sequential tethering of Golgins and catalysis of SNAREpin assembly by the vesicle-tethering protein p115. <i>Journal of Cell Biology</i> , 2002, 157, 45-62.	2.3	188
32	Hsp104 antagonizes α -synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. <i>Journal of Clinical Investigation</i> , 2008, 118, 3087-3097.	3.9	184
33	Heterochromatin anomalies and double-stranded RNA accumulation underlie <i>C9orf72</i> poly(PR) toxicity. <i>Science</i> , 2019, 363, .	6.0	181
34	A direct role for GRASP65 as a mitotically regulated Golgi stacking factor. <i>EMBO Journal</i> , 2003, 22, 3279-3290.	3.5	169
35	Small Heat Shock Proteins Potentiate Amyloid Dissolution by Protein Disaggregases from Yeast and Humans. <i>PLoS Biology</i> , 2012, 10, e1001346.	2.6	167
36	TDP-43 and RNA form amyloid-like myo-granules in regenerating muscle. <i>Nature</i> , 2018, 563, 508-513.	13.7	163

#	ARTICLE	IF	CITATIONS
37	Operational Plasticity Enables Hsp104 to Disaggregate Diverse Amyloid and Nonamyloid Clients. <i>Cell</i> , 2012, 151, 778-793.	13.5	162
38	A Cellular System that Degrades Misfolded Proteins and Protects against Neurodegeneration. <i>Molecular Cell</i> , 2014, 55, 15-30.	4.5	157
39	FUS and TDP-43 Phases in Health and Disease. <i>Trends in Biochemical Sciences</i> , 2021, 46, 550-563.	3.7	154
40	Hsp104, Hsp70 and Hsp40 interplay regulates formation, growth and elimination of Sup35 prions. <i>EMBO Journal</i> , 2008, 27, 2712-2724.	3.5	153
41	A Role for the Vesicle Tethering Protein, P115, in the Post-Mitotic Stacking of Reassembling Golgi Cisternae in a Cell-Free System. <i>Journal of Cell Biology</i> , 1999, 146, 57-70.	2.3	149
42	RNA-binding proteins with prion-like domains in ALS and FTLD-U. <i>Prion</i> , 2011, 5, 179-187.	0.9	140
43	Asymmetric deceleration of ClpB or Hsp104 ATPase activity unleashes protein-remodeling activity. <i>Nature Structural and Molecular Biology</i> , 2007, 14, 114-122.	3.6	139
44	Amyloid assembly and disassembly. <i>Journal of Cell Science</i> , 2018, 131, .	1.2	138
45	Itâ€™s Raining Liquids: RNA Tunes Viscoelasticity and Dynamics of Membraneless Organelles. <i>Molecular Cell</i> , 2015, 60, 189-192.	4.5	121
46	TDP-43 condensation properties specify its RNA-binding and regulatory repertoire. <i>Cell</i> , 2021, 184, 4680-4696.e22.	13.5	121
47	Loss of Dynamic RNA Interaction and Aberrant Phase Separation Induced by Two Distinct Types of ALS/FTD-Linked FUS Mutations. <i>Molecular Cell</i> , 2020, 77, 82-94.e4.	4.5	119
48	<i>C9orf72</i> poly(GR) aggregation induces TDP-43 proteinopathy. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	115
49	Hsp104: A Weapon to Combat Diverse Neurodegenerative Disorders. <i>NeuroSignals</i> , 2008, 16, 63-74.	0.5	108
50	Atypical AAA+ Subunit Packing Creates an Expanded Cavity for Disaggregation by the Protein-Remodeling Factor Hsp104. <i>Cell</i> , 2007, 131, 1366-1377.	13.5	107
51	CRISPR-Cas9 Screens Identify the RNA Helicase DDX3X as a Repressor of C9ORF72 (GGGGCC) _n Repeat-Associated Non-AUG Translation. <i>Neuron</i> , 2019, 104, 885-898.e8.	3.8	107
52	Spiral architecture of the Hsp104 disaggregase reveals the basis for polypeptide translocation. <i>Nature Structural and Molecular Biology</i> , 2016, 23, 830-837.	3.6	102
53	N-terminal Domains Elicit Formation of Functional Pmel17 Amyloid Fibrils. <i>Journal of Biological Chemistry</i> , 2009, 284, 35543-35555.	1.6	101
54	Higher-order organization of biomolecular condensates. <i>Open Biology</i> , 2021, 11, 210137.	1.5	96

#	ARTICLE	IF	CITATIONS
55	A Cryptic Rab1-binding Site in the p115 Tethering Protein. <i>Journal of Biological Chemistry</i> , 2005, 280, 25840-25848.	1.6	95
56	A synergistic small-molecule combination directly eradicates diverse prion strain structures. <i>Nature Chemical Biology</i> , 2009, 5, 936-946.	3.9	93
57	FUS inclusions disrupt RNA localization by sequestering kinesin-1 and inhibiting microtubule detyrosination. <i>Journal of Cell Biology</i> , 2017, 216, 1015-1034.	2.3	92
58	Structural basis for substrate gripping and translocation by the ClpB AAA+ disaggregase. <i>Nature Communications</i> , 2019, 10, 2393.	5.8	88
59	Motor Mechanism for Protein Threading through Hsp104. <i>Molecular Cell</i> , 2009, 34, 81-92.	4.5	84
60	Sequential SNARE disassembly and GATE-16-GOS-28 complex assembly mediated by distinct NSF activities drives Golgi membrane fusion. <i>Journal of Cell Biology</i> , 2002, 157, 1161-1173.	2.3	83
61	Fission Yeast Does Not Age under Favorable Conditions, but Does So after Stress. <i>Current Biology</i> , 2013, 23, 1844-1852.	1.8	83
62	The Hsp104 N-Terminal Domain Enables Disaggregase Plasticity and Potentiation. <i>Molecular Cell</i> , 2015, 57, 836-849.	4.5	83
63	Chaperones in Neurodegeneration. <i>Journal of Neuroscience</i> , 2015, 35, 13853-13859.	1.7	81
64	Discovery and Characterization of an Endogenous CXCR4 Antagonist. <i>Cell Reports</i> , 2015, 11, 737-747.	2.9	80
65	Mechanistic and Structural Insights into the Prion-Disaggregase Activity of Hsp104. <i>Journal of Molecular Biology</i> , 2016, 428, 1870-1885.	2.0	80
66	Spiraling in Control: Structures and Mechanisms of the Hsp104 Disaggregase. <i>Cold Spring Harbor Perspectives in Biology</i> , 2019, 11, a034033.	2.3	77
67	FUS Regulates Activity of MicroRNA-Mediated Gene Silencing. <i>Molecular Cell</i> , 2018, 69, 787-801.e8.	4.5	76
68	The Amino-terminal Domain of the Golgi Protein Giantin Interacts Directly with the Vesicle-tethering Protein p115. <i>Journal of Biological Chemistry</i> , 2000, 275, 2831-2836.	1.6	74
69	Potentiated Hsp104 variants suppress toxicity of diverse neurodegenerative disease-linked proteins. <i>DMM Disease Models and Mechanisms</i> , 2014, 7, 1175-84.	1.2	74
70	Molecular Dissection of FUS Points at Synergistic Effect of Low-Complexity Domains in Toxicity. <i>Cell Reports</i> , 2018, 24, 529-537.e4.	2.9	74
71	Applying Hsp104 to protein-misfolding disorders This paper is one of a selection of papers published in this special issue entitled 8th International Conference on AAA Proteins and has undergone the Journal's usual peer review process.. <i>Biochemistry and Cell Biology</i> , 2010, 88, 1-13.	0.9	73
72	Hsp104 Suppresses Polyglutamine-Induced Degeneration Post Onset in a <i>Drosophila</i> MJD/SCA3 Model. <i>PLoS Genetics</i> , 2013, 9, e1003781.	1.5	73

#	ARTICLE	IF	CITATIONS
73	A molecular tweezer antagonizes seminal amyloids and HIV infection. <i>ELife</i> , 2015, 4, .	2.8	71
74	Phosphorylation of the Vesicle-Tethering Protein P115 by a Casein Kinase IIâ€œLike Enzyme Is Required for Golgi Reassembly from Isolated Mitotic Fragments. <i>Journal of Cell Biology</i> , 2000, 150, 475-488.	2.3	69
75	Nuclear Import Receptors Directly Bind to Arginine-Rich Dipeptide Repeat Proteins and Suppress Their Pathological Interactions. <i>Cell Reports</i> , 2020, 33, 108538.	2.9	69
76	Hsp110 Chaperones Regulate Prion Formation and Propagation in <i>S. cerevisiae</i> by Two Discrete Activities. <i>PLoS ONE</i> , 2008, 3, e1763.	1.1	69
77	The elusive middle domain of Hsp104 and ClpB: Location and function. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2012, 1823, 29-39.	1.9	68
78	Engineering enhanced protein disaggregases for neurodegenerative disease. <i>Prion</i> , 2015, 9, 90-109.	0.9	68
79	Designer protein disaggregases to counter neurodegenerative disease. <i>Current Opinion in Genetics and Development</i> , 2017, 44, 1-8.	1.5	68
80	The metazoan protein disaggregase and amyloid depolymerase system. <i>Prion</i> , 2013, 7, 457-463.	0.9	67
81	A PDZâ€œBinding Motif Controls Basolateral Targeting of Syndecanâ€œ1 Along the Biosynthetic Pathway in Polarized Epithelial Cells. <i>Traffic</i> , 2008, 9, 1915-1924.	1.3	62
82	ALS/FTLD-Linked Mutations in FUS Glycine Residues Cause Accelerated Gelation and Reduced Interactions with Wild-Type FUS. <i>Molecular Cell</i> , 2020, 80, 666-681.e8.	4.5	62
83	The clinical trial landscape in amyotrophic lateral sclerosisâ€œPast, present, and future. <i>Medicinal Research Reviews</i> , 2020, 40, 1352-1384.	5.0	61
84	An NSF function distinct from ATPase-dependent SNARE disassembly is essential for Golgi membrane fusion. <i>Nature Cell Biology</i> , 1999, 1, 335-340.	4.6	58
85	The Surprising Role of Amyloid Fibrils in HIV Infection. <i>Biology</i> , 2012, 1, 58-80.	1.3	56
86	Biology and Pathobiology of TDP-43 and Emergent Therapeutic Strategies. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a024554.	2.9	56
87	Therapeutic Dissolution of Aberrant Phases by Nuclear-Import Receptors. <i>Trends in Cell Biology</i> , 2019, 29, 308-322.	3.6	55
88	DAXX represents a new type of protein-folding enabler. <i>Nature</i> , 2021, 597, 132-137.	18.7	54
89	Direct and selective elimination of specific prions and amyloids by 4,5-dianilinophthalimide and analogs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 7159-7164.	3.3	53
90	Combating deleterious phase transitions in neurodegenerative disease. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2021, 1868, 118984.	1.9	52

#	ARTICLE	IF	CITATIONS
91	The Mad2 partial unfolding model: regulating mitosis through Mad2 conformational switching. <i>Journal of Cell Biology</i> , 2008, 183, 761-768.	2.3	51
92	Conformational plasticity of the ClpAP AAA+ protease couples protein unfolding and proteolysis. <i>Nature Structural and Molecular Biology</i> , 2020, 27, 406-416.	3.6	51
93	Prime Time for \hat{A} -Synuclein. <i>Journal of Neuroscience</i> , 2007, 27, 2433-2434.	1.7	48
94	Emergence and natural selection of drug-resistant prions. <i>Molecular BioSystems</i> , 2010, 6, 1115.	2.9	48
95	Engineering therapeutic protein disaggregases. <i>Molecular Biology of the Cell</i> , 2016, 27, 1556-1560.	0.9	48
96	Engineering and Evolution of Molecular Chaperones and Protein Disaggregases with Enhanced Activity. <i>Frontiers in Molecular Biosciences</i> , 2016, 3, 8.	1.6	44
97	Skd3 (human ClpB) is a potent mitochondrial protein disaggregase that is inactivated by 3-methylglutaconic aciduria-linked mutations. <i>ELife</i> , 2020, 9, .	2.8	44
98	Prion proteostasis. <i>Prion</i> , 2008, 2, 135-140.	0.9	42
99	Conserved Distal Loop Residues in the Hsp104 and ClpB Middle Domain Contact Nucleotide-binding Domain 2 and Enable Hsp70-dependent Protein Disaggregation. <i>Journal of Biological Chemistry</i> , 2014, 289, 848-867.	1.6	42
100	Poly(ADP-ribose) drives condensation of FUS via a transient interaction. <i>Molecular Cell</i> , 2022, 82, 969-985.e11.	4.5	41
101	Hsp104 Drives \hat{A} -Protein-Only-Positive Selection of Sup35 Prion Strains Encoding Strong [PSI]. <i>Chemistry and Biology</i> , 2012, 19, 1400-1410.	6.2	40
102	Phase separation of RNA-binding proteins in physiology and disease: An introduction to the JBC Reviews thematic series. <i>Journal of Biological Chemistry</i> , 2019, 294, 7113-7114.	1.6	39
103	TRIM11 Prevents and Reverses Protein Aggregation and Rescues a Mouse Model of Parkinson's Disease. <i>Cell Reports</i> , 2020, 33, 108418.	2.9	39
104	Disease mutations in the prion-like domains of hnRNPA1 and hnRNPA2/B1 introduce potent steric zippers that drive excess RNP granule assembly. <i>Rare Diseases (Austin, Tex)</i> , 2013, 1, e25200.	1.8	38
105	Disparate Mutations Confer Therapeutic Gain of Hsp104 Function. <i>ACS Chemical Biology</i> , 2015, 10, 2672-2679.	1.6	38
106	Characterization of HNRNPA1 mutations defines diversity in pathogenic mechanisms and clinical presentation. <i>JCI Insight</i> , 2021, 6, .	2.3	38
107	Escaping amyloid fate. <i>Nature Structural and Molecular Biology</i> , 2008, 15, 544-546.	3.6	37
108	Reversing deleterious protein aggregation with re-engineered protein disaggregases. <i>Cell Cycle</i> , 2014, 13, 1379-1383.	1.3	37

#	ARTICLE	IF	CITATIONS
109	Mechanistic Insights into Hsp104 Potentiation. <i>Journal of Biological Chemistry</i> , 2016, 291, 5101-5115.	1.6	37
110	Potentiating Hsp104 activity via phosphomimetic mutations in the middle domain. <i>FEMS Yeast Research</i> , 2018, 18, .	1.1	37
111	Mining Disaggregase Sequence Space to Safely Counter TDP-43, FUS, and $\hat{I}\pm$ -Synuclein Proteotoxicity. <i>Cell Reports</i> , 2019, 28, 2080-2095.e6.	2.9	36
112	Repurposing Hsp104 to Antagonize Seminal Amyloid and Counter HIV Infection. <i>Chemistry and Biology</i> , 2015, 22, 1074-1086.	6.2	34
113	Membrane traffic: Do cones mark sites of fission?. <i>Current Biology</i> , 2000, 10, R141-R144.	1.8	32
114	Engineered protein disaggregases mitigate toxicity of aberrant prion-like fusion proteins underlying sarcoma. <i>Journal of Biological Chemistry</i> , 2019, 294, 11286-11296.	1.6	31
115	Emerging small-molecule therapeutic approaches for amyotrophic lateral sclerosis and frontotemporal dementia. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 126942.	1.0	31
116	Supramolecular Mechanism of Viral Envelope Disruption by Molecular Tweezers. <i>Journal of the American Chemical Society</i> , 2020, 142, 17024-17038.	6.6	31
117	Structure of <i>Calcarisporiella thermophila</i> Hsp104 Disaggregase that Antagonizes Diverse Proteotoxic Misfolding Events. <i>Structure</i> , 2019, 27, 449-463.e7.	1.6	29
118	Navigating the ClpB channel to solution. <i>Nature Structural and Molecular Biology</i> , 2005, 12, 4-6.	3.6	28
119	Phasing in and out. <i>Nature Chemistry</i> , 2016, 8, 528-530.	6.6	28
120	Poly(ADP-ribose) Engages the TDP-43 Nuclear-Localization Sequence to Regulate Granulo-Filamentous Aggregation. <i>Biochemistry</i> , 2018, 57, 6923-6926.	1.2	28
121	Protein-Remodeling Factors As Potential Therapeutics for Neurodegenerative Disease. <i>Frontiers in Neuroscience</i> , 2017, 11, 99.	1.4	27
122	RNA-Binding Proteins in Amyotrophic Lateral Sclerosis and Neurodegeneration. <i>Neurology Research International</i> , 2012, 2012, 1-5.	0.5	26
123	Arginine-rich dipeptide-repeat proteins as phase disruptors in C9-ALS/FTD. <i>Emerging Topics in Life Sciences</i> , 2020, 4, 293-305.	1.1	26
124	Heterozygous variants of <i>CLPB</i> are a cause of severe congenital neutropenia. <i>Blood</i> , 2022, 139, 779-791.	0.6	25
125	Sexually dimorphic RNA helicases DDX3X and DDX3Y differentially regulate RNA metabolism through phase separation. <i>Molecular Cell</i> , 2022, 82, 2588-2603.e9.	4.5	24
126	(Dis)Solving the problem of aberrant protein states. <i>DMM Disease Models and Mechanisms</i> , 2021, 14, .	1.2	23

#	ARTICLE	IF	CITATIONS
127	Hydrogen exchange reveals Hsp104 architecture, structural dynamics, and energetics in physiological solution. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 7333-7342.	3.3	22
128	Biochemical Timekeeping Via Reentrant Phase Transitions. <i>Journal of Molecular Biology</i> , 2021, 433, 166794.	2.0	22
129	Enhancement of Ebola virus infection by seminal amyloid fibrils. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 7410-7415.	3.3	21
130	Epigallocatechin-3-gallate rapidly remodels PAP85-120, SEM1(45-107), and SEM2(49-107) seminal amyloid fibrils. <i>Biology Open</i> , 2015, 4, 1206-1212.	0.6	20
131	Heterozygous frameshift variants in HNRNPA2B1 cause early-onset oculopharyngeal muscular dystrophy. <i>Nature Communications</i> , 2022, 13, 2306.	5.8	20
132	Countering amyloid polymorphism and drug resistance with minimal drug cocktails. <i>Prion</i> , 2010, 4, 244-251.	0.9	18
133	The extent of Ssa1/Ssa2 Hsp70 chaperone involvement in nuclear protein quality control degradation varies with the substrate. <i>Molecular Biology of the Cell</i> , 2020, 31, 221-233.	0.9	18
134	Liquidizing <sc>FUS</sc> via prion-like domain phosphorylation. <i>EMBO Journal</i> , 2017, 36, 2925-2927.	3.5	17
135	Hsp104 and Potentiated Variants Can Operate as Distinct Nonprocessive Translocases. <i>Biophysical Journal</i> , 2019, 116, 1856-1872.	0.2	17
136	AAA+ Protein-Based Technologies to Counter Neurodegenerative Disease. <i>Biophysical Journal</i> , 2019, 116, 1380-1385.	0.2	17
137	Therapeutic genetic variation revealed in diverse Hsp104 homologs. <i>ELife</i> , 2020, 9, .	2.8	17
138	Suramin Inhibits Hsp104 ATPase and Disaggregase Activity. <i>PLoS ONE</i> , 2014, 9, e110115.	1.1	16
139	Switching Condensates: The CTD Code Goes Liquid. <i>Trends in Biochemical Sciences</i> , 2020, 45, 1-3.	3.7	16
140	Structural and mechanistic insights into Hsp104 function revealed by synchrotron X-ray footprinting. <i>Journal of Biological Chemistry</i> , 2020, 295, 1517-1538.	1.6	16
141	Structural and kinetic basis for the regulation and potentiation of Hsp104 function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 9384-9392.	3.3	16
142	Purification of Hsp104, a Protein Disaggregase. <i>Journal of Visualized Experiments</i> , 2011, , .	0.2	15
143	Prion-like Domains Program Ewing's Sarcoma. <i>Cell</i> , 2017, 171, 30-31.	13.5	15
144	Avidity for Polypeptide Binding by Nucleotide-Bound Hsp104 Structures. <i>Biochemistry</i> , 2017, 56, 2071-2075.	1.2	14

#	ARTICLE	IF	CITATIONS
145	Specific aromatic foldamers potently inhibit spontaneous and seeded A β ²⁴² and A β ²⁴³ fibril assembly. <i>Biochemical Journal</i> , 2014, 464, 85-98.	1.7	13
146	Isolating Potentiated Hsp104 Variants Using Yeast Proteinopathy Models. <i>Journal of Visualized Experiments</i> , 2014, , e52089.	0.2	13
147	Nuclear-Import Receptors Counter Deleterious Phase Transitions in Neurodegenerative Disease. <i>Journal of Molecular Biology</i> , 2022, 434, 167220.	2.0	13
148	AAA+ proteins: one motor, multiple ways to work. <i>Biochemical Society Transactions</i> , 2022, 50, 895-906.	1.6	13
149	Editorial: The Role of AAA+ Proteins in Protein Repair and Degradation. <i>Frontiers in Molecular Biosciences</i> , 2018, 5, 85.	1.6	12
150	Shock and awe: unleashing the heat shock response to treat Huntington disease. <i>Journal of Clinical Investigation</i> , 2011, 121, 2972-2975.	3.9	12
151	Heat shock protein Grp78/BiP/HspA5 binds directly to TDP-43 and mitigates toxicity associated with disease pathology. <i>Scientific Reports</i> , 2022, 12, 8140.	1.6	12
152	TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity.. <i>Journal of Biological Chemistry</i> , 2009, 284, 25459.	1.6	11
153	Expression and Purification of Recombinant Skd3 (Human ClpB) Protein and Tobacco Etch Virus (TEV) Protease from <i>Escherichia coli</i> . <i>Bio-protocol</i> , 2020, 10, e3858.	0.2	11
154	Atomic Structures of Amyloid- β ² Oligomers Illuminate a Neurotoxic Mechanism. <i>Trends in Neurosciences</i> , 2020, 43, 740-743.	4.2	10
155	Just Took a DNA Test, Turns Out 100% Not That Phase. <i>Molecular Cell</i> , 2020, 78, 193-194.	4.5	10
156	N-alpha-acetylation of Huntingtin protein increases its propensity to aggregate. <i>Journal of Biological Chemistry</i> , 2021, 297, 101363.	1.6	9
157	Fleeting Amyloid-like Forms of Rim4 Ensure Meiotic Fidelity. <i>Cell</i> , 2015, 163, 275-276.	13.5	7
158	TDP-43 shapeshifts to encipher FTD severity. <i>Nature Neuroscience</i> , 2019, 22, 3-5.	7.1	7
159	Sequestration of TDP-43 ²¹⁶⁻⁴¹⁴ Aggregates by Cytoplasmic Expression of the proSAAS Chaperone. <i>ACS Chemical Neuroscience</i> , 2022, 13, 1651-1665.	1.7	6
160	Ubiquilin 2: Shuttling Clients Out of Phase?. <i>Molecular Cell</i> , 2018, 69, 919-921.	4.5	5
161	Aggregates of TDP-43 protein spiral into view. <i>Nature</i> , 2022, 601, 29-30.	13.7	4
162	Tau heckles speckles: A pathogenic mechanism in tauopathy?. <i>Neuron</i> , 2021, 109, 1585-1587.	3.8	3

#	ARTICLE	IF	CITATIONS
163	Open Access: A Role for p53 in c9ALS/FTD?. Trends in Genetics, 2021, 37, 404-406.	2.9	3
164	Karyopherin- β 2 Inhibits and Reverses Aggregation and Liquid-liquid Phase Separation of the ALS/FTD-Associated Protein FUS. Bio-protocol, 2020, 10, e3725.	0.2	3
165	Flying under the radar: TMEM106B(120-254) fibrils break out in diverse neurodegenerative disorders. Cell, 2022, 185, 1290-1292.	13.5	3
166	Susan Lee Lindquist (1949-2016). Nature, 2016, 540, 40-40.	13.7	2
167	3' UTRs in the Eye of the TIGER. Developmental Cell, 2018, 47, 544-546.	3.1	2
168	The Sense of Targeting Nonsense-Mediated Decay in C9-ALS/FTD. Neuron, 2020, 106, 6-9.	3.8	1
169	Counteracting Semen-mediated Enhancement of HIV Infection and Enveloped Virus Infection by a Lysine-specific Molecular Tweezer. AIDS Research and Human Retroviruses, 2014, 30, A263-A263.	0.5	0
170	Susan Lee Lindquist (1949-2016). Trends in Biochemical Sciences, 2017, 42, 169-170.	3.7	0
171	Developing RNA Therapeutics for TDP43 Proteinopathy in ALS/FTD. FASEB Journal, 2022, 36, .	0.2	0
172	Increased Nuclear Localization of Engineered Hsp104 Variants Mitigates α S, FUS, and TDP43 Toxicity in Yeast. FASEB Journal, 2022, 36, .	0.2	0
173	Identifying Therapeutic Inhibitors of TDP43 Phase Separation. FASEB Journal, 2022, 36, .	0.2	0
174	Elucidating the mechanism of potentiated Hsp104 NBD2 variants against proteotoxicity. FASEB Journal, 2022, 36, .	0.2	0
175	Developing therapeutic protein disaggregases for Neurodegenerative Disease. FASEB Journal, 2022, 36, .	0.2	0